To Dope or Not to Dope: Neuroenhancement with Prescription Drugs and Drugs of Abuse among Swiss University Students

This was a cross-sectional survey study—not an experiment. The researchers tested nothing in the sense of giving people drugs. Instead, they tested the **prevalence** of a behaviour: whether healthy university students had ever used prescription medications (e.g., methylphenidate/Ritalin, sedatives, beta-blockers) or drugs of abuse (e.g., alcohol, cannabis, amphetamines, cocaine) specifically for the purpose of "neuroenhancement"—defined as improving mood, cognition, or academic performance.

They compared:

**Prescription drug users** vs. non-users

**Drug of abuse users** vs. non-users

**"Soft enhancer" users** (coffee, energy drinks, vitamins, tonics) vs. prescription/drug users

**Demographic subgroups** (gender, age, field of study, stress levels, prior illicit drug use)

The outcome measures were:

Lifetime prevalence of neuroenhancement (ever used)

12-month prevalence (used in past year)

30-day prevalence (used in past month)

Frequency of use (daily, weekly, monthly, less often)

Self-reported reasons for use (e.g., "to increase learning," "to relax," "to cope with performance pressure")

**Sample size:** 6,275 students who completed the survey (from an initial pool of 28,118 contacted)

**Population:** Students at three Swiss universities: University of Zurich, University of Basel, and Swiss Federal Institute of Technology Zurich (ETH Zurich)

**Setting:** Online survey, conducted between December 2012 and February 2013

**Demographics:** Mean age approximately 23–24 years; 57% female; 43% male; all academic disciplines represented (humanities, social sciences, natural sciences, engineering, medicine, law, economics)

**Key inclusion:** Currently enrolled students at one of the three institutions

**Key exclusion:** None explicitly stated beyond non-completion of survey

The researchers developed a custom online questionnaire (not a validated scale) because no standardised instrument existed for measuring neuroenhancement at the time. The survey included:

**Demographics:** Age, gender, field of study, semester (year of study)

**Substance use history:** Lifetime, past-year, and past-month use of 14 specific substances (both prescription and illicit), with follow-up questions about whether use was specifically for neuroenhancement (not recreational or medical)

**Stress measurement:** A single-item self-report question: "How stressed do you feel in your current study situation?" rated on a 5-point Likert scale (1 = not at all stressed, 5 = extremely stressed)

**Reasons for use:** A checklist of 10 possible motivations (e.g., "to increase learning," "to relax/sleep better," "to reduce nervousness," "to cope with performance pressure," "to increase performance," "experimentation")

**Soft enhancer use:** Frequency of coffee, energy drinks, vitamins, and tonics in the month before exams

**Illicit drug history:** Lifetime use of any illicit drug (not specifically for enhancement)

The survey was anonymous and took approximately 15–20 minutes to complete. No biological verification (e.g., urine tests, hair analysis) was used to confirm self-reported drug use.

**Study design:** Cross-sectional observational survey. This is a one-time snapshot of a population—not a longitudinal study that follows people over time, and certainly not a randomised controlled trial.

**Sampling:** All enrolled students at the three universities (approximately 28,118 total) were invited via institutional email lists to participate. This is a convenience sample within a defined population—not a random sample. Students self-selected to complete the survey.

**Response rate:** 6,275 completed surveys out of 28,118 contacted = 22.3% response rate. This is moderate for online surveys but raises concerns about non-response bias (students who chose to respond may differ systematically from those who ignored the email).

**Statistical approach:** Descriptive statistics (percentages, means) and inferential tests (chi-square tests for categorical comparisons, logistic regression for multivariate analysis). They reported odds ratios (OR) with 95% confidence intervals (CI) for predictors of neuroenhancement.

**What this design can prove:**

It can estimate the **prevalence** of a behaviour in a specific population at a specific time

It can identify **correlates** (e.g., students with higher stress are more likely to report use)

It can generate hypotheses about who might be at risk

**What this design cannot prove:**

**Causation:** It cannot tell us whether stress causes drug use, or drug use causes stress, or both are caused by something else (e.g., personality traits, study demands)

**Temporal order:** Because it's cross-sectional, we don't know if drug use preceded stress or vice versa

**Actual effectiveness:** The survey asks about *reasons* for use (e.g., "to increase learning") but does not measure whether the drugs actually improved learning or grades

**Generalisability:** Swiss university students in 2012–2013 may not represent students in other countries, cultures, or time periods (e.g., the rise of Adderall in the US, or newer drugs like modafinil)

**Major methodological weaknesses:**

1. **Self-report bias:** Students may underreport illicit drug use due to social desirability, or overreport if they want to appear "edgy." No biological verification.

2. **Definition of "neuroenhancement":** The survey asked specifically about use "to improve mood or cognitive function." But students might use a drug for multiple reasons (e.g., Ritalin recreationally at a party, then study the next day). The survey may not capture mixed motivations.

3. **Low response rate (22.3%):** Non-responders may be systematically different. For example, students who are very busy studying (and thus more likely to use enhancers) might have ignored the email. Or students who never use drugs might have been less interested in a survey about drugs.

4. **Single-item stress measure:** A one-question Likert scale is not a validated stress assessment (compare to the Perceived Stress Scale, which has 10–14 items).

5. **No control for academic performance:** We don't know if neuroenhancement users actually had better grades, worse grades, or the same grades as non-users.

**Overall prevalence:**

**13.8%** of respondents reported using prescription drugs (7.6%) or drugs of abuse including alcohol (7.8%) at least once specifically for neuroenhancement

Note: These categories overlap—some students used both, so the total is not simply the sum

**Most commonly used prescription drugs for neuroenhancement:**

Methylphenidate (Ritalin, Concerta): **4.1%** lifetime use

Sedatives (benzodiazepines, Z-drugs): **2.7%** lifetime use

Beta-blockers (e.g., propranolol for performance anxiety): **1.2%** lifetime use

Antidepressants: **0.6%** lifetime use

Other prescription drugs (e.g., modafinil, donepezil): <0.5%

**Most commonly used drugs of abuse for neuroenhancement:**

Alcohol: **5.6%** lifetime use (specifically to enhance mood or reduce anxiety before exams/presentations)

Cannabis: **2.5%** lifetime use (for relaxation or sleep improvement)

Amphetamines (speed, Adderall): **0.4%** lifetime use

Cocaine: **0.2%** lifetime use

Ecstasy/MDMA: **0.1%** lifetime use

**Frequency of use:**

Among those who used prescription drugs for neuroenhancement, **only 0.2%** used them daily

Most users (approximately 70%) used them "less than once per month" or "only before exams"

"Soft enhancers" (coffee, energy drinks, vitamins) were used daily by **30–40%** of students in the month before exams

**Reasons for neuroenhancement (multiple answers allowed):**

To increase learning/study efficiency: **66.2%**

To relax or improve sleep: **51.2%**

To reduce nervousness (e.g., before exams or presentations): **39.1%**

To cope with performance pressure: **34.9%**

To increase performance (general): **32.2%**

Experimentation/curiosity: **20.0%**

To reduce fatigue: **18.5%**

To improve mood: **15.3%**

**Predictors of neuroenhancement (logistic regression):**

**More senior students** (higher semester) were significantly more likely to use: odds ratio (OR) = 1.12 per additional year of study (95% CI: 1.06–1.18, p < 0.001)

**Higher self-reported stress** was associated with increased use: OR = 1.35 per point on the 5-point stress scale (95% CI: 1.25–1.46, p < 0.001)

**Prior illicit drug use** (any lifetime use of an illicit drug, not for enhancement) was the strongest predictor: OR = 4.82 (95% CI: 4.02–5.78, p < 0.001)

**Male gender** was associated with higher use: OR = 1.42 (95% CI: 1.20–1.68, p < 0.001)

**Field of study** showed some variation: students in natural sciences and engineering had slightly higher rates than humanities students, but differences were small (OR ~1.2–1.3)

**Soft enhancers vs. hard enhancers:**

Coffee was used daily by **38%** of all students in the month before exams

Energy drinks were used daily by **4%** , weekly by **15%**

Vitamins/tonics were used daily by **32%**

Prescription drugs or drugs of abuse were used daily by **<0.5%**

This is a prevalence study, so "effect size" refers to the magnitude of associations, not treatment effects.

**Stress as a predictor:** For every 1-point increase on the 5-point stress scale, the odds of using neuroenhancers increased by 35%. This is a moderate-to-strong association. To put it in perspective: a student who rates their stress as "5" (extremely stressed) has roughly 3.4 times the odds of using neuroenhancers compared to a student who rates stress as "1" (not at all stressed), assuming other factors are equal.

**Prior illicit drug use:** Students who had ever used any illicit drug (recreationally) were nearly **5 times more likely** to also use drugs for neuroenhancement. This is a very strong association—the strongest in the study.

**Gender difference:** Males were about **1.4 times more likely** than females to report neuroenhancement. This is a modest but statistically significant difference.

**Overall prevalence:** 13.8% translates to roughly **1 in 7 students** having tried neuroenhancement at least once. However, daily use was vanishingly rare (0.2%), meaning the "typical" user might try Ritalin a few times before exams, not pop pills every morning.

**Acknowledged by authors:**

Cross-sectional design prevents causal conclusions

Self-report data may be subject to recall bias and social desirability bias

Low response rate (22.3%) limits generalisability

The survey did not assess actual academic performance or cognitive function

The definition of "neuroenhancement" may have been interpreted differently by different students

**Additional critical limitations:**

**No validated stress scale:** The single-item stress question is psychometrically weak. A proper stress assessment (e.g., Perceived Stress Scale, 10 items) would have been more reliable.

**No control for personality traits:** Traits like conscientiousness, neuroticism, or sensation-seeking are known to predict both drug use and academic behaviour. Without measuring these, the associations with stress and gender could be confounded.

**No data on dosage or frequency beyond crude categories:** "Less than once per month" could mean once a year or once every two years. This limits our understanding of actual exposure.

**Survey conducted in 2012–2013:** The landscape of neuroenhancement has changed. Modafinil, for example, was barely mentioned (<0.5%) but has since become more popular in some student populations. Adderall (mixed amphetamine salts) is less common in Switzerland than in the US.

**Swiss context:** Switzerland has different drug policies, healthcare systems, and academic cultures than other countries. Results may not generalise to US, UK, or Asian universities.

**No biological verification:** Self-reported drug use is notoriously unreliable. Students may underreport illicit drug use due to stigma or legal concerns, or overreport if they perceive the survey as "cool."

For someone running their own n=1 experiment on neuroenhancement:

### What to test (specific intervention and dose)

**If testing prescription stimulants:** Methylphenidate (Ritalin) at 10–20 mg oral, immediate-release, taken 30–60 minutes before a study session. Note: This requires a prescription in most countries—do not obtain illegally.

**If testing caffeine (the most common "soft enhancer"):** 100–200 mg (1–2 cups of coffee) or 50–100 mg if you're caffeine-naive. This is legal, safe, and widely available.

**If testing beta-blockers for performance anxiety:** Propranolol 10–40 mg, taken 60–90 minutes before a presentation or exam. Again, prescription required.

**Do NOT test:** Alcohol, cannabis, amphetamines, or cocaine for cognitive enhancement. The risks (addiction, psychosis, cardiovascular events, legal consequences) far outweigh any potential benefits, and the evidence for cognitive enhancement with these substances is weak to non-existent.

### Minimum meaningful duration

**For a single-subject experiment:** Run for at least **2–4 weeks** to account for placebo effects, learning effects, and day-to-day variability in mood and sleep.

**For caffeine:** A crossover design (1 week caffeine, 1 week placebo, 1 week caffeine) is ideal. Each phase should be at least **5–7 days** to allow for adaptation.

**For prescription stimulants:** Because of tolerance and side effects, a single-dose test (one study session with drug, one with placebo, separated by 48+ hours) is more realistic than a long-term trial.

### What to measure (specific metrics)

**Primary outcome:** Objective cognitive performance. Use a validated online test battery (e.g., Cambridge Brain Sciences, Lumosity, or the NIH Toolbox) that measures:

- Working memory (e.g., digit span, n-back task)

- Processing speed (e.g., reaction time, symbol search)

- Sustained attention (e.g., continuous performance test)

- Executive function (e.g., Stroop test, task switching)

**Secondary outcomes:**

- Subjective focus/concentration (0–10 scale, hourly)

- Subjective anxiety (0–10 scale, before and after study session)

- Sleep quality (Pittsburgh Sleep Quality Index, or simply sleep onset latency and total sleep time via a sleep diary)

- Side effects (headache, jitteriness, nausea, appetite loss—track daily